1289P - Treatments and outcome of NSCLC patients who receive gefitinib for more than three years

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Cytotoxic agents
Non-small-cell lung cancer
Biological therapy
Presenter Kyoko Otsuka
Authors K. Otsuka1, N. Katakami2, A. Hata3, R. Kaji3, S. Fujita3, K. Nagata4, A. Nakagawa4, R. Tachikawa4, K. Otsuka4, K. Tomii4
  • 1Respiratory Medicine Dept., Kobe City Medical Center, General Hospital, Kobe/JP
  • 2Division Of Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe/JP
  • 3Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe/JP
  • 4Respiratory Medicine, Kobe City Medical Center, General Hospital, Kobe/JP



Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutation initially respond well to gefitinib, but most of them revealed acquired resistance after approximately 10 months. However, some patients can obtain clinical benefit from gefitinib for several years. Little is known regarding characteristics, clinical course, and treatment strategy of these patients. The aim of our study was to evaluate how these patients obtain longer clinical benefit, by analysis for patients receiving gefitinib for over three years.


Between July 2002 and September 2011, 18 NSCLC patients received gefitinib for more than three years. We retrospectively evaluated patient characteristics, treatment strategy, prescription period, progression-free survival (PFS), and overall survival (OS) from gefitinib initiation.


Median age was 71 (range: 50-87), male/female = 3/15, All of them had adenocarcinoma, performance status (PS) 0 or 1 / 2 = 17/1, smoking status: never/former =13/5, previous treatment regimen:0/1/2 = 5/8/5, EGFR mutation status: mutated/wild-type/unknown = 7/3/8, mutation site: exon 19 (deletion) / exon 21 (L858R)/others = 4/2/1, stage: recurrence/stage IV = 10/8. Five patients still continue gefitinib without disease progression (PD). Among 13 patients with PD, 4 switched to another regimen, 2 received local treatments (metastectomy and stereotactic body radiation therapy) for progressive primary site, 7 continued gefitinib in spite of progressive disease status, and 3 of 7 continued gefitinib with radiotherapy to progressive metastatic sites (brain and bone). Median prescription period, PFS, and OS from gefitinib initiation were 54.0 months (95% confidence interval (CI): 47.8, 61.7 months), 47.9 months (95%CI: 36.4, 74.9 months), and 80.2 months (95%CI: 62.0, undeterminable months), respectively.


In patients receiving gefitinib over 3 years, median survival was notably over 80 months. Even after PD, multimodal personalized therapy with continuous gefitinib administration and/or additional local treatment may prolong survival of some NSCLC patients with EGFR mutation.


All authors have declared no conflicts of interest.